Drugs Made In America Acquisition II Corp. Ordinary Shares
DMII
NASDAQ·Financial Services·Financial - Conglomerates·Mkt cap $647.8M
$10.17
▲ 0.00%
P/E
33.56
Mkt Cap
$647.8M
52-Wk Range
$9.86–$10.21
52-Week Range
$9.86 - $10.21
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 2.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Strategic focus on domestic drug manufacturing reshoring trend
- Experienced management team in pharmaceutical industry
- First-mover advantage in SPAC consolidation of domestic pharma
- Access to capital markets for acquisition financing
Bear Case
1 risk
- Low volatility (beta 0.0).
Growth
No forward estimates available
Government incentives for domestic pharmaceutical manufacturing
Value
Valuation data unavailable
Momentum
Stable
+0.9% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DMII right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Most recent quarter reported revenue of $0. Reported EPS of $0.07.
Reported EPS · last 4Q
Q2 26
$0.07
Q1 26
$0.07
Q4 25
$0.18
Q3 25
-$0.02
Revenue trend · last 7Q
—
—
—
—
—
—
—
Q3 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
Margins · last 7Q
No margin history available.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How DMII stacks vs Financial - Conglomerates
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.